BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12475538)

  • 1. The management of ureteric obstruction secondary to malignant pelvic disease.
    Chitale SV; Scott-Barrett S; Ho ET; Burgess NA
    Clin Radiol; 2002 Dec; 57(12):1118-21. PubMed ID: 12475538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Endoluminal therapy for bilateral malignant ureteric obstruction].
    Liu YD; Yuan J; Huang ST; Luo JT; Zeng GH; Xun L
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):717-9. PubMed ID: 18246808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of retrograde ureteric stenting as a urinary drainage procedure in ureteric obstruction related to malignant lesions.
    Wijayarathna S; Suvendran S; Ishak M; Weligamage A; Epa A; Munasinghe S; Abeygunaskera AM
    Ceylon Med J; 2014 Dec; 59(4):124-7. PubMed ID: 25556408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of percutaneous nephrostomy in malignant ureteric obstruction.
    Wilson JR; Urwin GH; Stower MJ
    Ann R Coll Surg Engl; 2005 Jan; 87(1):21-4. PubMed ID: 15720902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of antegrade stenting in the management of the obstructed kidney.
    Sharma SD; Persad RA; Haq A; Appleton DS; Doyle PT; Bullock KN; Doble A
    Br J Urol; 1996 Oct; 78(4):511-5. PubMed ID: 8944505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-stage tubeless antegrade ureteric stenting: a safe and cost-effective option?
    Chitale S; Raja V; Hussain N; Saada J; Girling S; Irving S; Cockburn JF
    Ann R Coll Surg Engl; 2010 Apr; 92(3):218-24. PubMed ID: 19995490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrograde or antegrade double-pigtail stent placement for malignant ureteric obstruction?
    Uthappa MC; Cowan NC
    Clin Radiol; 2005 May; 60(5):608-12. PubMed ID: 15851050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percutaneous nephrostomy for ureteric obstruction due to advanced pelvic malignancy: have we got the balance right?
    Misra S; Coker C; Richenberg J
    Int Urol Nephrol; 2013 Jun; 45(3):627-32. PubMed ID: 23666587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percutaneous nephrostomy in the management of malignant ureteric obstruction.
    Teenan RP; Ramsay A; Deane RF
    Br J Urol; 1989 Sep; 64(3):238-40. PubMed ID: 2804559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Galdakao-modified Valdivia position in endoscopic management of malignant ureteric obstruction.
    Emam A; Elmoazen M; Shabayek M; Zriek AM; Gad HH
    Int Urol Nephrol; 2022 Mar; 54(3):463-468. PubMed ID: 35084651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of metal stents for managing malignant ureteric obstruction.
    Sountoulides P; Kaplan A; Kaufmann OG; Sofikitis N
    BJU Int; 2010 Apr; 105(8):1066-72. PubMed ID: 20067458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of extrinsic malignant ureteral obstruction with urinary diversion.
    Kanou T; Fujiyama C; Nishimura K; Tokuda Y; Uozumi J; Masaki Z
    Int J Urol; 2007 Aug; 14(8):689-92. PubMed ID: 17681056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To tube or not to tube? Utilising a tubeless antegrade ureteric stenting system in a tertiary referral hospital.
    Looney AT; Daly PJA; Cullen IM; MacMahon P; Kelly IMG
    Ir J Med Sci; 2019 Feb; 188(1):283-288. PubMed ID: 29696559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined antegrade and retrograde endoscopic retroperitoneal bypass of ureteric strictures: a modification of the 'rendezvous' procedure.
    Yates DR; Mehta SS; Spencer PA; Parys BT
    BJU Int; 2010 Apr; 105(7):992-7. PubMed ID: 19712115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous antegrade ureteric stent insertion in malignant disease.
    Harding JR
    J R Soc Med; 1993 Sep; 86(9):511-3. PubMed ID: 8410885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical application of fluoroscopic guided percutaneous antegrade ureteral stents placement for the treatment of malignant ureteral obstruction.
    Liu Y; Wu K; Lai H; Zeng Z; Zhang B
    J Xray Sci Technol; 2019; 27(3):453-460. PubMed ID: 30909269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of antegrade stenting for lower ureteric obstruction.
    Jenkins CN; Marcus AJ
    J R Soc Med; 1995 Aug; 88(8):446-9. PubMed ID: 7562827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined antegrade and retrograde ureteral stenting: the rendezvous technique.
    Macrì A; Magno C; Certo A; Basile A; Scuderi G; Crescenti F; Famulari C
    Clin Radiol; 2005 Feb; 60(2):257-60. PubMed ID: 15664581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metallic ureteric stents: early experience.
    Pandian SS; Hussey JK; McClinton S
    Br J Urol; 1998 Dec; 82(6):791-7. PubMed ID: 9883213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Likelihood of retrograde double-J stenting according to ureteral obstructing pathology.
    Danilovic A; Antonopoulos IM; Mesquita JL; Lucon AM
    Int Braz J Urol; 2005; 31(5):431-6; discussion 436. PubMed ID: 16255788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.